Predictors of GON Blockade Success in Migraine
ConditionMigraine
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBaşakşehir Çam & Sakura City Hospital
About this trial
This multicenter, prospective cohort study aims to identify clinical and demographic predictors that influence the success of greater occipital nerve (GON) block in patients with migraine.
Patients will be evaluated at baseline, on each injection day, and at one- and three-month follow-ups. Study parameters include demographics, migraine type and duration, comorbidities, headache characteristics, treatment history, and validated outcome measures such as the Numeric Rating Scale (NRS), Headache Impact Test-6 (HIT-6), and Global Rating of Change (GRoC).
The goal is to establish predictive factors of treatment success in order to optimize patient selection and contribute robust multicenter evidence to individualized migraine management
Eligibility criteria
Qualifiers
Diagnosis of migraine for at least 6 months, according to ICHD-3 criteria
Age between 18 and 65 years
Inadequate response to preventive therapy used regularly for at least 3 months
Planned treatment with greater occipital nerve block (GONB) and provision of signed informed consent
Disqualifiers
Pregnancy or breastfeeding
Presence of malignancy
Coagulopathy or anticoagulant therapy
Local infection, open wound, or history of surgery at the injection site preventing the procedure
Trial design
Treatments tested in this trial
- Greater Occipital Nerve (GON) Blockade
Treatment groups
460 Participants
are divided into 1 treatment groupSponsors and collaborators
Başakşehir Çam & Sakura City Hospital
Lead sponsor
Umraniye Education and Research Hospital
Collaborator
Gaziantep City Hospital
Collaborator
Namik Kemal University School of Medicine, Tekirdag
Collaborator
Bakırçay University, Faculty of Medicine
Collaborator
Source ClinicalTrials.gov